Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
08 feb 2007 - 08:03
Statutaire naam
Crucell N.V.
Titel
Crucell and DSM intensify collaboration and development of PER.C6® human cell line
Bericht
Sittard/Leiden, The Netherlands, February 8, 2007 – DSM Biologics, a business unit of DSM Pharmaceuticals, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that they have further intensified their PER.C6® collaboration, by executing an agreement to expand the existing commercial relationship to include new classes of proteins, including biosimilar protein products. As part of the agreement, DSM paid Crucell an undisclosed amount in exchange for additional license rights and a higher share of future licensing income.
Since December 2002, DSM Biologics and Crucell are jointly outlicensing PER.C6® human cell line to third parties as a production platform for monoclonal antibodies and recombinant proteins. The parties recently established the PERCIVIA PER.C6® Development Center in Cambridge, Mass, USA as a joint venture to further develop the PER.C6® cell line and provide a unique solution for the production of pharmaceutical proteins to licensees utilizing the PER.C6® human cell line in the biotech industry.
Datum laatste update: 10 januari 2026